Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
VALENCIA, Calif., Feb. 16, 2016 -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery and development of therapeutic products for diabetes, announced today that it will present at the RBC Capital Markets 2016 Healthcare Conference on Tuesday, February 23, 2016 at 10:00 AM (ET) at The Palace Hotel, in New York, NY.
Presenting from the Company will be its Chief Executive Officer, Matthew Pfeffer.
Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.
About MannKind Corporation
MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD) focuses on the discovery and development of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.
Company Contact: Matthew J. Pfeffer Chief Executive Officer (661) 775-5300 [email protected]
